Riskpilot← Back to searchSign inGet full accessBiopotent AB
ABActiveOrg 5591165443Rabygatan 9Temporary employment agency activities and other human resource provisions · NACE 7820Est. 20172 employees
Revenue 2024
SEK 4,9M
+10% vs 2023
EBITDA margin
15.6%
+3% vs 2023
Equity ratio
18.1%
Financial strength
Net profit 2024
SEK 345K
+52% vs 2023
| Revenue | SEK 4,9M | +10% |
| EBITDA | SEK 760K | +3% |
| Net profit | SEK 345K | +52% |
| Total assets | SEK 3M | -15% |
| Equity | SEK 549K | +35% |
| Employees | 2 | — |
Legal name
Biopotent AB
Org number
5591165443
Legal form
Aktiebolag
NACE code
7820 · Temporary employment agency activities and other human resource provisions
Founded
21 juni 2017
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Rekrytering och konsultverksamhet inom nordisk medicinteknik, läkemedelsindustri och sjukvård
Address
Rabygatan 9
Email
biopotent@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 336 | 6 144 | 6 588 | 4 433 | 4 865 |
| Staff expenses | — | — | — | −2 760 | −2 804 |
| EBITDA | 1 294 | 812 | 901 | 740 | 760 |
| Depreciation & amort. | −267 | −277 | −270 | −286 | −357 |
| EBIT | 1 027 | 535 | 631 | 454 | 403 |
| Net financials | −14 | −6 | — | 9 | −44 |
| Profit before tax | 740 | 382 | 440 | 331 | 483 |
| Tax | −175 | −91 | −116 | −104 | −138 |
| Net profit | 565 | 291 | 324 | 228 | 345 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 678 | 2 377 | 2 732 | 3 560 | 3 038 |
| Equity | 621 | 412 | 375 | 408 | 549 |
| Long-term debt | 14 | 0 | 0 | 449 | 246 |
| Short-term debt | 1 137 | 912 | 1 143 | 1 358 | 1 021 |
| Total debt | 1 151 | 912 | 1 143 | 1 807 | 1 268 |
EBITDA margin
15.6%
This company
15.8%
Market median
+1% vs market
20202024
Equity ratio
18.1%
This company
38.2%
Market median
-53% vs market
20202024
Return on equity
62.9%
This company
18.4%
Market median
+242% vs market
20202024
Net profit margin
7.1%
This company
8.1%
Market median
-12% vs market
20202024
Asset turnover
1.60×
This company
1.12×
Market median
+43% vs market
20202024
Debt / equity
4.54×
This company
0.62×
Market median
-632% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PO | Audit | 2024 |
| Former (1) | ||
SM Audit | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biopotent AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Mattias Lamme | Audit | 0 companies |
| Per Olof Henry Ranstam | Audit | 0 companies |
| Hans Ingemar Mattsson | Board of Directors | 0 companies |
| Arthur Eskil Preben Foxryd | Deputy Board Member | 0 companies |